Key Takeaways
- aTyr Pharma has granted nonstatutory stock options for 12,200 shares to two new employees.
- The options have an exercise price of $0.98 per share, equivalent to the stock’s closing price on February 17, 2026.
- aTyr is developing treatments for fibrosis and inflammation using its tRNA synthetase platform, with efzofitimod as its lead candidate.
Stock Options Granted to New Employees
aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical-stage biotechnology company, announced on February 20, 2026, that its Compensation Committee has granted two employees nonstatutory stock options to acquire an aggregate of 12,200 shares of common stock. The exercise price for these options is set at $0.98 per share, which matches the closing price of aTyr’s stock on the Nasdaq Capital Market as of February 17, 2026.
These stock options were awarded as an employment incentive in line with Nasdaq Listing Rule 5635(c)(4) and are part of the aTyr Pharma, Inc. 2022 Inducement Plan. The vesting schedule for the options spans four years, with 25% of the shares vesting after one year and the remaining 75% vesting in equal monthly increments over the subsequent three years, contingent on ongoing employment with aTyr.
About aTyr Pharma
aTyr Pharma is dedicated to the discovery and development of first-in-class medicines through its proprietary tRNA synthetase platform. This platform utilizes evolutionary intelligence to translate the biology of tRNA synthetases, which are critical proteins with unique properties that can regulate various biological pathways in humans.
The company’s primary focus is to identify therapeutic intervention points by exploring signaling pathways driven by its exclusive library derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate, efzofitimod, is currently under clinical development for interstitial lung disease, a category of immune-mediated disorders characterized by inflammation and progressive scarring of lung tissue.
For additional information, visit www.atyrpharma.com.
The content above is a summary. For more details, see the source article.